# US 9,753,037 B2 · Biomarker panel for detecting lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,753,037 B2
- Document ID: US9753037B2
- Status: Granted
- Kind: B2
- Application number: 14/206,486
- Filed: 2014-03-12
- Published: 2014-09-18
- Granted: 2017-09-05
- Earliest claimed: 2013-03-15
- Assignees: Rush University Medical Center
- Applicants: Rush University Medical Center
- Inventors: Jeffrey A. Borgia; Michael Liptay
- Web page: https://patentgrep.com/patent/US9753037B2

## CPC

- G01N 33/5752: of the lungs
- G01N 2333/54: Interleukins [IL]
- G01N 2333/555: Interferons [IFN]
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least two biomarkers selected from the group consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, MIP-1α, sIL-2Rα, CA-125, sE-Selectin, Eotaxin, sEGFR, MMP-2, OPN, MCP-1, CRP, sICAM-1 and CYFRA 21.1. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a group and determining whether the subject is at risk for lung cancer based on the group.

## Claims

### Claim 1

A method of measuring a panel of biomarkers in a subject suspected of having non-small cell lung cancer, the method comprising:
obtaining a biological sample from the subject;
determining a measurement for the panel of biomarkers in the biological sample, the panel consisting of IL-6, IL-1ra, IL-10, SDF-1α+β, TNF-α, and MIP-1α, wherein the measurement comprises measuring a level of each biomarker in the panel.

### Claim 2 (depends on 1)

The method according to claim 1, comprising determining the measurement for the panel of biomarkers wherein the panel further comprises sIL-2Rα.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the measurement is obtained after detection of an indeterminate nodule is found by low-dose computed tomography (LDCT) detection.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the measurement is a primary screen.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the subject is a “high risk” subject for lung cancer.

### Claim 6 (depends on 1)

The method according to claim 1, comprising using a learning statistical classifier system to analyze the measurement of the panel of biomarkers.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the learning statistical classifier system is a Random Forest system.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the panel has a misclassification error of less than 20%.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the Random Forest system comprises 1000 cross-validated classification trees.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the biological sample comprises plasma sample or serum sample.